B-Cell Lymphoma Cells Overexpressing BMI-1 Are Correlated with Drug Resistance through Enhanced Expression of Survivin and Are Effectively Eliminated by T Cells with Anti-CD38 Chimeric Receptor

被引：0
|
作者：
Bhattacharyya, Joyeeta [1 ]
Mihara, Keichiro [1 ]
Ohtsubo, Motoaki [2 ]
Yasunaga, Shin'ichiro [2 ]
Takihara, Yoshihiro [2 ]
Hoshi, Masaharu [3 ]
Kimura, Akiro [1 ]
机构：
[1] Hiroshima Univ, Dept Hematol & Oncol, Res Inst Radiat Biol & Med, Hiroshima, Japan
[2] Hiroshima Univ, Dept Stem Cell Biol, Res Inst Radiat Biol & Med, Hiroshima, Japan
[3] Hiroshima Univ, Dept Radiat Biophys, Res Inst Radiat Biol & Med, Hiroshima, Japan
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1488 / 1488
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study
    Huang, Chen
    Wu, Lili
    Liu, Ruixia
    Li, Weijing
    Li, Zheng
    Li, Jianqiang
    Liu, Lihong
    Shan, Baoen
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (17)
  • [42] Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma
    Xin, Xiangke
    Zhu, Xiaojian
    Yang, Yang
    Wang, Na
    Wang, Jue
    Xu, Jinhuan
    Wei, Jia
    Huang, Liang
    Zheng, Miao
    Xiao, Yi
    Li, Chunrui
    Cao, Yang
    Meng, Fankai
    Jiang, Lijun
    Zhang, Yicheng
    CELLULAR ONCOLOGY, 2024, 47 (04) : 1425 - 1440
  • [43] Anomalous expression of Thy1 (CD90) in B-cell lymphoma cells and proliferation inhibition by anti-Thy1 antibody treatment
    Ishiura, Yoshihito
    Kotani, Norihiro
    Yamashita, Ryusuke
    Yamamoto, Harumi
    Kozutsumi, Yasunori
    Honke, Koichi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 396 (02) : 329 - 334
  • [44] Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
    Yan, Zi-Xun
    Li, Li
    Wang, Wen
    OuYang, Bin-Shen
    Cheng, Shu
    Wang, Li
    Wu, Wen
    Xu, Peng-Peng
    Muftuoglu, Muharrem
    Hao, Ming
    Yang, Su
    Zhang, Mu-Chen
    Zheng, Zhong
    Li, James
    Zhao, Wei-Li
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 6995 - 7003
  • [45] The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: a meta-analysis
    Zhou, Hui
    Luo, Yuling
    Zhu, Sha
    Wang, Xi
    Zhao, Yunuo
    Ou, Xuejin
    Zhang, Tao
    Ma, Xuelei
    BMC CANCER, 2018, 18
  • [46] The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
    Hui Zhou
    Yuling Luo
    Sha Zhu
    Xi Wang
    Yunuo Zhao
    Xuejin Ou
    Tao Zhang
    Xuelei Ma
    BMC Cancer, 18
  • [47] Significantly targeting rituximab resistant B-cell lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells.
    Chu, Yaya
    Ayello, Janet
    Yahr, Ashlin
    Katz, Jared
    Lo, Lowrence
    Flowers, Allyson
    Cairo, Mitchell S.
    CANCER RESEARCH, 2013, 73
  • [48] CD20-Specific Chimeric Antigen Receptor- Expressing T Cells As Salvage Therapy in Rituximab-Refractory CD20(+) B-Cell Non-Hodgkin Lymphoma
    Li, Xin
    Cheng, Qian
    Liu, Rui
    Kang, Liqing
    Xu, Nan
    Li, Minghao
    Yu, Lei
    BLOOD, 2021, 138
  • [49] Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Tu, Sanfang
    Zhou, Lijuan
    Huang, Rui
    Zhou, Xuan
    Yang, Jilong
    Li, Meifang
    Jin, Bo
    Wang, Langqi
    Zhuo, Yaqi
    Chen, Huifang
    Chang, Lung-Ji
    Li, Yuhua
    BLOOD, 2023, 142
  • [50] CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma
    Cheng, Qian
    Tan, Jingwen
    Liu, Rui
    Kang, Liqing
    Zhang, Yi
    Wang, Erhua
    Li, Ying
    Zhang, Jian
    Xiao, Han
    Xu, Nan
    Li, Minghao
    Yu, Lei
    Li, Xin
    CYTOTHERAPY, 2022, 24 (10) : 1026 - 1034
12345